Peptide Therapy

Peptide Therapy · BPC-157

BPC-157

BPC-157 — the "body protection compound" — is one of the most discussed recovery peptides. It's studied for potential roles in tissue repair, gut health, and angiogenesis.

It's also a peptide where the gap between popularity and proof is real, so we treat it with appropriate care.

We measure first. Then we act.

What it's explored for

What BPC-157 is explored for

Offered only to eligible patients after clinical evaluation. Results vary. BPC-157 is most often explored for tissue and recovery support. The research to date is largely preclinical, which shapes how and when we'd consider it — always under clinical oversight, never as a default.
BPC-157 also appears in two combination protocols we offer: the Wolverine Stack (with TB-500) and the Glow Stack (with TB-500 and GHK-Cu).
Low noise. High signal.

An honest word on the evidence

This matters here more than almost anywhere. For BPC-157, there are not yet high-quality, long-term human studies confirming the benefits people hope for — much of the evidence is preclinical. That's exactly why it belongs under clinical care, with quality sourcing, monitoring, and honest expectations. If it isn't right for you, we'll say so.
The bigger picture

Who it's for

BPC-157 is most often considered by active adults focused on recovery, and sometimes by midlife men alongside a broader plan.
Peptide Therapy
Our model

How it works at ACT 2 Health

Every plan follows one path. Each step feeds the next. See the Peptide Therapy approach.

  1. 01

    Measure

    A baseline of labs and history, and a clear read on your goals.

  2. 02

    Plan

    A clinician decides whether it fits — and what to address first.

  3. 03

    Act

    If appropriate, you begin with clear guidance and support.

  4. 04

    Track

    We monitor how you respond on a defined cadence.

  5. 05

    Adjust

    Protocols are refined over time. Guided care, not a kit in the mail.

Questions

Frequently asked questions

  • The honest answer: much of the evidence is preclinical, and high-quality long-term human data is limited. We consider it for eligible patients with realistic expectations, not promises.

  • Safety depends on the source, dose, and oversight. We only consider it under clinical evaluation and monitoring, with attention to quality sourcing.

  • Regulatory status for peptides varies and changes over time. Our clinicians work within applicable regulations and will explain what applies.

  • The Wolverine and Glow stacks combine BPC-157 with other peptides for broader recovery or skin support. A clinician helps determine what fits.

Own your next chapter

Ready to start with clarity?

We measure first. Then we act.

ACT 2 Health provides clinician-led care. Treatments described are available only to eligible patients following clinical evaluation and within applicable regulations. This page is educational and is not medical advice. Individual results vary.